{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:04:43Z","timestamp":1793084683922,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bone.2025.117523","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:02:39Z","timestamp":1747310559000},"page":"117523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Comparative effectiveness of romosozumab versus teriparatide for fracture prevention: A new-user, active comparator design"],"prefix":"10.1016","volume":"198","author":[{"given":"Ryoji","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyoshi","family":"Ikenoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakuya","family":"Niihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Aita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahisa","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2025.117523_bb0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2025.117523_bb0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2025.117523_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2025.117523_bb0020","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1093\/ejendo\/lvae076","article-title":"Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?","volume":"191","author":"Anastasilakis","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2025.117523_bb0025","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2025.117523_bb0030","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1210\/clinem\/dgae484","article-title":"The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis","volume":"110","author":"Hartz","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117523_bb0035","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-024-07255-6","article-title":"Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study","author":"Masuda","year":"2024","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0040","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2025.117523_bb0045","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2025.117523_bb0050","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study","volume":"110","author":"Stokar","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117523_bb0055","first-page":"190","article-title":"Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young","volume":"5","author":"Okada","year":"2022","journal-title":"Middle-aged, and Elderly People, JMA J"},{"key":"10.1016\/j.bone.2025.117523_bb0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bone.2025.117523_bb0065","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/pds.3477","article-title":"Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia\u00ae (denosumab) for the treatment of postmenopausal osteoporosis","volume":"22","author":"Xue","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2025.117523_bb0070","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2025.117523_bb0075","article-title":"Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications","volume":"20","author":"Hayes","year":"2024","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2025.117523_bb0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/pds.5490","article-title":"Core concepts in pharmacoepidemiology: measures of drug utilization based on individual-level drug dispensing data","volume":"31","author":"Rasmussen","year":"2022","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2025.117523_bb0085","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","article-title":"Interpretation and use of FRAX in clinical practice","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0090","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/jbmr.3807","article-title":"The design and validation of a new algorithm to identify incident fractures in administrative claims data","volume":"34","author":"Wright","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117523_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-011-1559-4","article-title":"Algorithms can be used to identify fragility fracture cases in physician-claims databases","volume":"23","author":"Jean","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00776-010-1543-4","article-title":"Nationwide one-decade survey of hip fractures in Japan","volume":"15","author":"Hagino","year":"2010","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.bone.2025.117523_bb0105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2106\/00004623-198163050-00012","article-title":"Closed treatment of subtrochanteric fractures of the femur in a modified cast-brace","volume":"63","author":"Delee","year":"1981","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bone.2025.117523_bb0110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.2022.1816","article-title":"Causal directed acyclic graphs","volume":"327","author":"Lipsky","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2025.117523_bb0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/EDE.0b013e318225c2be","article-title":"DAGitty: a graphical tool for analyzing causal diagrams","volume":"22","author":"Textor","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.bone.2025.117523_bb0120","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac009","article-title":"Assessment of coding-based frailty algorithms for long-term outcome prediction among older people in community settings: a cohort study from the Shizuoka Kokuho Database","volume":"51","author":"Nishimura","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.bone.2025.117523_bb0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jbmr\/zjad019","article-title":"Frailty increases the long-term risk for fall and fracture-related hospitalizations and all-cause mortality in community-dwelling older women","volume":"39","author":"Dent","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117523_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2188\/jea.JE20200288","article-title":"History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan","volume":"31","author":"Hayashida","year":"2021","journal-title":"J. Epidemiol."},{"key":"10.1016\/j.bone.2025.117523_bb0135","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"10.1016\/j.bone.2025.117523_bb0140","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.bone.2025.117523_bb0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bone.2025.117523_bb0150","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117523_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","article-title":"An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis","volume":"39","author":"Li","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.bone.2025.117523_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10428","article-title":"Trends in hip fracture incidence in Japan: estimates based on nationwide hip fracture surveys from 1992 to 2017","volume":"5","author":"Takusari","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2025.117523_bb0165","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00198-022-06657-8","article-title":"Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review","volume":"34","author":"Chandran","year":"2023","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0170","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1359\/JBMR.040109","article-title":"Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo osteoporosis epidemiology study","volume":"19","author":"Chang","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117523_bb0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s001980170121","article-title":"Hip fracture incidence rates Singapore 1991\u20131998","volume":"12","author":"Koh","year":"2001","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s001980050144","article-title":"International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization program for research on aging","volume":"9","author":"Schwartz","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0185","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2025.117523_bb0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2025.117523_bb0195","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117523_bb0200","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","article-title":"Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases","volume":"47","author":"Miyauchi","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117523_bb0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bone.2025.117523_bb0210","doi-asserted-by":"crossref","first-page":"e1967","DOI":"10.1210\/clinem\/dgae347","article-title":"Letter to the editor from Kawaguchi: \u201ccardiovascular safety of romosozumab vs PTH analogs for osteoporosis treatment: a propensity score matched cohort study\u201d","volume":"109","author":"Kawaguchi","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117523_bb0215","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/pds.4208","article-title":"Validity of major osteoporotic fracture diagnosis codes in the clinical data analysis and reporting system in Hong Kong","volume":"26","author":"Sing","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2025.117523_bb0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S444447","article-title":"Validity of major osteoporotic fracture diagnoses in the Danish National Patient Registry","volume":"16","author":"Clausen","year":"2024","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.bone.2025.117523_bb0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ggi.14124","article-title":"ZEVIOUS group, validating care-needs level against self-reported measures of functioning, disability and sarcopenia among Japanese patients receiving home medical care: the Zaitaku evaluative initiatives and outcome study","volume":"21","author":"Tsugihashi","year":"2021","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0230","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00198-017-3909-3","article-title":"Worldwide prevalence and incidence of osteoporotic vertebral fractures","volume":"28","author":"Ballane","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117523_bb0235","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00774-024-01530-6","article-title":"Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021","volume":"42","author":"Soen","year":"2024","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2025.117523_bb0240","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/CIA.S107285","article-title":"Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin. Interv. Aging"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:17:23Z","timestamp":1778941043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"alternative-id":["S8756328225001358"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117523","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of romosozumab versus teriparatide for fracture prevention: A new-user, active comparator design","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117523"}}